Phibro Animal Health Reports 17% Revenue Growth to $1.52 Billion for Fiscal Year Ending June 30, 2026

Phibro Animal Health Corporation reported significant financial growth for the fiscal year ending June 30, 2026, with net sales reaching $1.52 billion, a 17% increase from $1.30 billion in the previous year. The company's gross profit also rose to $512.5 million, reflecting a 28% increase compared to $399.9 million in fiscal 2025. This growth was primarily driven by a 21% increase in the Animal Health segment, which generated $1.16 billion in sales, bolstered by the acquisition of Zoetis's medicated feed additive portfolio, which contributed $146.1 million in incremental revenue.

The company’s profitability improved markedly, with net income climbing to $99.7 million, up from $48.3 million in the prior year. This increase was attributed to higher gross profit margins, which improved to 33.8% from 30.9%, despite rising input and distribution costs. Selling, general, and administrative expenses also increased by 10% to $318.1 million, reflecting costs associated with the acquisition and ongoing operational initiatives. Interest expenses rose 28% to $44.4 million, largely due to higher debt levels following the acquisition financing.

Phibro's strategic developments included the completion of the acquisition of Zoetis's medicated feed additive portfolio for approximately $297.5 million, which was finalized on October 31, 2024. This acquisition not only expanded Phibro's product offerings but also included six manufacturing sites across the U.S., Italy, and China. The integration of these assets is expected to enhance the company's operational capabilities and market reach, particularly in the growing global animal health market.

Operationally, Phibro serves approximately 4,800 customers across 90 countries, with a diverse product portfolio that includes around 790 product lines. The company has seen increased demand for its nutritional specialty products and vaccines, particularly in North America and Latin America. However, the Performance Products segment experienced a decline in sales, dropping 8% to $73.5 million, attributed to lower demand for ingredients used in personal care products. The company also reported a workforce of approximately 2,605 employees as of June 30, 2026, reflecting its commitment to expanding its operational capabilities.

Looking ahead, Phibro anticipates continued growth driven by global demand for animal protein and the expansion of its product offerings. However, the company faces challenges, including regulatory scrutiny over the use of medically important antimicrobials and potential impacts from geopolitical tensions, particularly in regions where it operates manufacturing facilities. The company remains focused on integrating its recent acquisitions and enhancing its product development pipeline to sustain its competitive position in the animal health industry.